Abstract

Recently, tissue segment binding method with a hydrophilic radioligand [ 3H]-CGP12177 was developed to detect plasma membrane β-adrenoceptors in rat heart (Horinouchi et al., 2006). In the present study, propranolol (40 mg kg − 1 day − 1 ), atenolol (40 mg kg − 1 day − 1 ) and bevantolol (200 mg kg − 1 day − 1 ) were administered to rats for 6 weeks, and the changes of plasma membrane β-adrenoceptors and their mRNA expression in rat ventricle were examined. Chronic administration of propranolol increased the β 1-adrenoceptors but decreased the β 2-adrenoceptors without changing total amount of plasma membrane β-adrenoceptors. Atenolol increased both plasma membrane β 1- and β 2-adrenoceptors, whereas bevantolol had no effect on the β-adrenoceptor density and their subtype proportions. In contrast, the density of β-adrenoceptors detected in conventional homogenate binding study was extremely low (approximately 60% of plasma membrane β-adrenoceptors detected with the tissue segment binding method) and the effects of chronic administration of β-adrenoceptor antagonists were not necessarily in accord with those at the plasma membrane β-adrenoceptors. The mRNA levels of β 1- and β 2-adrenoceptors were not altered by propranolol treatment, while β 1-adrenoceptor mRNA significantly decreased after administration of atenolol or bevantolol without changing the level of β 2-adrenoceptor mRNA. The present binding study with intact tissue segments clearly shows that the plasma membrane β 1- and β 2-adrenoceptors of rat heart, in contrast to the homogenate binding sites and the mRNA levels, are differently affected by chronic treatment with three β-adrenoceptor antagonists; up- and down-regulations of β 1- and β 2-adrenoceptors, respectively, by propranolol, and up-regulation of both the subtypes by atenolol, but no significant change in both the subtypes by bevantolol.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.